1276:HKEXJiangsu Hengrui Pharmaceuticals Co.,Ltd Analysis

Jiangsu Hengrui Pharma is trading at HK$55.15, well below its 20‑day SMA of 58.01, its 50‑day SMA of 63.24 and the 200‑day SMA of 71.65, indicating a bearish price stance. Technical signals reinforce this view: RSI sits at 40.5, the MACD line is below its signal line, and the histogram is negative, while volume is rising and 30‑day volatility is a lofty 45.5%, suggesting heightened short‑term risk. The stock appears overvalued given a DCF fair value of roughly HK$27.8 and a trailing P/E of 39 × versus an industry average of 24.8 ×.
Fundamentally the company is robust – revenue of HK$32.6 bn grew 13% YoY, gross margin is an impressive 86%, operating margin 31%, and cash on hand exceeds HK$40 bn with negligible debt, delivering a ROE of 14.5%. The recent licensing and co‑development agreement with Bristol‑Myers Squibb, potentially worth up to $15 bn and covering 13 oncology, hematology and immunology programs, adds a strong catalyst for future growth.
In the near term the stock faces pressure from technical weakness and valuation concerns, but the long‑run narrative is supported by a deep pipeline, ample liquidity and a strategic partnership that could unlock significant upside, provided regulatory and geopolitical headwinds are managed.